WO2014193964A3 - Prognostic and predictive breast cancer signature - Google Patents

Prognostic and predictive breast cancer signature Download PDF

Info

Publication number
WO2014193964A3
WO2014193964A3 PCT/US2014/039807 US2014039807W WO2014193964A3 WO 2014193964 A3 WO2014193964 A3 WO 2014193964A3 US 2014039807 W US2014039807 W US 2014039807W WO 2014193964 A3 WO2014193964 A3 WO 2014193964A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
methods
prognostic
tet1
breast cancer
Prior art date
Application number
PCT/US2014/039807
Other languages
French (fr)
Other versions
WO2014193964A2 (en
Inventor
Marsha Rosner
Miao SUN
Original Assignee
Marsha Rosner
Sun Miao
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Marsha Rosner, Sun Miao filed Critical Marsha Rosner
Publication of WO2014193964A2 publication Critical patent/WO2014193964A2/en
Publication of WO2014193964A3 publication Critical patent/WO2014193964A3/en
Priority to US14/952,265 priority Critical patent/US10679730B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Compositions, kits and methods for treating cancer in a subject involving one or more upstream activators and/or downstream effectors of the ten-eleven translocation (TET) methylcytosine dioxygenase 1 (TET1) are disclosed. Specifically, the disclosure provides methods for diagnosing a subject with at least one of a decreased survival rate, a poor prognosis, a faster progression of the cancer by analyzing a biological sample from the subject for the expression of high mobility group AT-hook 2 (HMGA2), TET1, and homeobox A (HOXA) genes including HOXA7 and HOXA9; and methods for treating cancer comprising administering a DNA demethylation agent.
PCT/US2014/039807 2013-05-28 2014-05-28 Prognostic and predictive breast cancer signature WO2014193964A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/952,265 US10679730B2 (en) 2013-05-28 2015-11-25 Prognostic and predictive breast cancer signature

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828103P 2013-05-28 2013-05-28
US61/828,103 2013-05-28

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/952,265 Continuation-In-Part US10679730B2 (en) 2013-05-28 2015-11-25 Prognostic and predictive breast cancer signature

Publications (2)

Publication Number Publication Date
WO2014193964A2 WO2014193964A2 (en) 2014-12-04
WO2014193964A3 true WO2014193964A3 (en) 2015-08-13

Family

ID=51989519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/039807 WO2014193964A2 (en) 2013-05-28 2014-05-28 Prognostic and predictive breast cancer signature

Country Status (1)

Country Link
WO (1) WO2014193964A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9476100B1 (en) * 2015-07-06 2016-10-25 Nucleix Ltd. Methods for diagnosing bladder cancer
CN107630093B (en) * 2017-11-09 2020-12-18 上海千贝医疗科技有限公司 Reagent, kit, detection method and application for diagnosing liver cancer
CN111500717A (en) * 2019-01-30 2020-08-07 中国医学科学院基础医学研究所 Application of 5-hydroxymethylcytosine in evaluating metastatic potential of breast cancer and treating breast cancer
IL265451B (en) 2019-03-18 2020-01-30 Frumkin Dan Methods and systems for detecting methylation changes in dna samples

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192100A1 (en) * 2005-05-04 2009-07-30 Axel Vater Novel use of spiegelmers
US20100048499A1 (en) * 2006-12-14 2010-02-25 Desai Neil P Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090192100A1 (en) * 2005-05-04 2009-07-30 Axel Vater Novel use of spiegelmers
US20100048499A1 (en) * 2006-12-14 2010-02-25 Desai Neil P Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US20120114670A1 (en) * 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ACOSTA ET AL.: "DNA methylation changes in murine breast adenocarcinomas allow the identification of candidate genes for human breast carcinogenesis.", MAMM GENOME, vol. 22, no. 3-4, 2011, pages 249 - 59, XP019889999 *
GILBERT ET AL.: "HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype.", J CLIN INVEST., vol. 120, no. 5, 2010, pages 1535 - 50, XP055217871 *
HAGEMANN ET AL.: "Azacytidine and Decitabine Induce Gene -Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines.", PLOS ONE., vol. 6, no. 3, 2011, pages E17388, XP055217876 *
HSU ET AL.: "TET1 Suppresses Cancer Invasion by Activatingthe Tissue Inhibitors of Metalloproteinases.", CELL REP., vol. 2, no. 3, 2012, pages 568 - 79, XP055217867 *
SUN ET AL.: "HMGA2/TET1/HOXA9 signaling pathway regulatesbreast cancer growth and metastasis.", PROC NATL ACAD SCI USA., vol. 110, no. 24, 11 June 2013 (2013-06-11), pages 9920 - 5, XP055217879 *
WEND ET AL.: "WNT10B/b-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.", EMBO MOL MED., vol. 5, no. 2, February 2013 (2013-02-01), pages 264 - 79, XP055217866 *

Also Published As

Publication number Publication date
WO2014193964A2 (en) 2014-12-04

Similar Documents

Publication Publication Date Title
Santoni et al. Urinary markers in bladder cancer: an update
Kandimalla et al. Genome-wide analysis of CpG island methylation in bladder cancer identified TBX2, TBX3, GATA2, and ZIC4 as pTa-specific prognostic markers
Balgkouranidou et al. Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
MA39951A (en) Detection of dna that originates from a specific cell-type and related methods
MX355416B (en) Lung cancer biomarkers and uses thereof.
WO2013033629A3 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
MX341517B (en) Pancreatic cancer biomarkers and uses thereof.
MX355020B (en) Lung cancer biomarkers and uses thereof.
WO2012167145A3 (en) Genome-scale analysis of aberrant dna methylation in colorectal cancer
GB201015765D0 (en) Use of myeloid cell biomarkers for the diagnosis of cancer
WO2009037572A3 (en) Biomarker combinations for colorectal cancer
WO2009037438A8 (en) Improved detection of mage-a expression
WO2010118016A3 (en) Digital quantification of dna methylation
WO2014193964A3 (en) Prognostic and predictive breast cancer signature
WO2007087612A8 (en) Detection and diagnosis of smoking related cancers
WO2012162660A3 (en) Methods using dna methylation for identifying a cell or a mixture of cells for prognosis and diagnosis of diseases, and for cell remediation therapies
WO2009149026A3 (en) Genomic approaches to fetal treatment and diagnosis
Langevin et al. Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients
WO2011087709A3 (en) Eml4-alk translocations in lung cancer
EP3140420B1 (en) Breast cancer epigenetic markers useful in anthracycline treatment prognosis
EP2513340A4 (en) Mean dna copy number of chromosomal regions is of prognostic significance in cancer
MX2013008252A (en) Prognostic signature for colorectal cancer recurrence.
Strand et al. RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy
BR112013021056A2 (en) monoclonal antibody, hybridoma cell line, diagnostic kit, methods for producing a monoclonal antibody and binding agent, purified amino acid sequence binding agent, method for obtaining a coding nucleic acid sequence, antibody molecule encoding isolated nucleic acid, vector, isolated host cell, fusion protein, screening method for the presence of a disease, a condition, methods of diagnosing an individual, prognosis for an individual, and monitoring an individual, and , method for detecting the presence or absence of cervical cancer
WO2012083274A3 (en) Methods for diagnosis, prognosis and methods of treatment

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14804265

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14804265

Country of ref document: EP

Kind code of ref document: A2